Document 0068
 DOCN  M9590068
 TI    [Chemotherapy and vaccine against HIV infection]
 DT    9509
 AU    Kimura S; Department of Infectious Diseases and Applied Immunology,;
       Institute of Medical Science, University of Tokyo.
 SO    Rinsho Ketsueki. 1995 May;36(5):445-50. Unique Identifier : AIDSLINE
       MED/95302657
 AB    Anti-HIV treatment is the major strategy against HIV infection and AIDS.
       Nucleoside reverse transcriptase inhibitors have been studied
       extensively, and some of them have been approved for clinical use.
       Efficacy of non-nucleoside reverse transcriptase inhibitors and
       HIV-protease inhibitors are also being confirmed. It became clear,
       however, that all of these agent, allow emergence of drug-resistant HIV
       mutants when used as monotherapy. Therefore, combination therapy or
       alternating therapy using these and other new agents may become the main
       mode of treatment in the future. Clinical trials for HIV vaccines are
       now being conducted in U.S.A. and other countries. In many of them,
       immunological responses were confirmed, although clinical benefit was
       not known yet. Vaccines which induce cellular immunity against broad
       spectrum of epitopes are desired to overcome viral mutations. Gene
       therapy is very attractive, and extensive studies are being conducted in
       many laboratories including ours. Methodology for early and correct
       diagnosis of opportunistic infections are now developing especially by
       using molecular technology. Steady improvement in the clinical
       management of opportunistic infections is achieved.
 DE    Acquired Immunodeficiency Syndrome/DRUG THERAPY/*THERAPY  AIDS
       Vaccines/*THERAPEUTIC USE  English Abstract  Human  HIV Infections/DRUG
       THERAPY/*THERAPY  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).